Objective: Elevated blood levels of endogenous digitalis-like factors (EDLF) may decrease erythrocyte sodium pump activity in preeclampsia. As the highest EDLF levels might be expected in severe preeclampsia, we investigated sodium pump activity in that group of patients.
Introduction
Preeclampsia is associated with abnormalities in many systems, 1, 2 among which are disorders of ion transport in maternal, neonatal and placental cell lines. 3 These include intracellular ion imbalances such as increased sodium and calcium, abnormalities that are also described in cases of essential hypertension. 4, 5 A common hypothesis to explain these abnormalities in preeclampsia has been the presence of placenta-derived endogenous digitalis-like factor(s) (EDLFs) in plasma. 3 These factors, which resemble or are identical to cardiotonic steroids, inhibit the sodium/potassium adenosine triphosphatase (Na/K ATPase) enzyme transport complex, which functions as the sodium pump (SP). Inhibition of this enzyme has several effects that could lead to an increase in vascular resistance and hence to some of the manifestations of preeclampsia. 6, 7 A circulating, biologically active EDLF would be expected to inhibit Na/K ATPase on the surface of erythrocyte membranes. Some previous studies in pregnancy and preeclampsia have been in accord with this prediction, but others have not. 3 These prior studies of erythrocyte Na/K ATPase activity in preeclampsia have been performed using a variety of techniques on a heterogeneous group of subjects, including those with mild and severe preeclampsia and pregnancy-induced hypertension. As this heterogeneous population might contribute to the variable results, we conducted the following study based on the hypothesis that EDLF levels would be highest and therefore erythrocyte Na/K ATPase activity would be maximally suppressed in severe preeclampsia rather than in the other clinical subcategories.
Methods
Three groups of subjects were recruited from the obstetrical clinics of the Wake Forest University School of Medicine, Winston Salem, NC, USA. Twelve subjects were enrolled into each of the following three groups: (1) normotensive non-pregnant subjects with full reproductive capability; (2) normotensive pregnant subjects and (3) subjects with pregnancies complicated by severe preeclampsia. Groups 2 and 3 were matched for gestational age.
Subjects were included in group 3 if they had at least one of the following American College of Obstetricians and Gynecologists criteria for severe preeclampsia: blood pressure >160-180 mm Hg systolic or >110 mm Hg diastolic; proteinuria >5 g per 24 h or 3 þ or greater on dipstick on two random urine samples collected at least 4 h apart; oliguria defined as less than 500 ml urine in 24 h; pulmonary edema; hepatocellular dysfunction (elevated aspartate aminotransferase or alanineaminotransferase) and visual or cerebral disturbances. 8 Blood samples were taken from the subjects with preeclampsia not more than 4 h prior to delivery.
All blood samples were collected aseptically, after informed consent was obtained for this Human Investigational Review Board-approved protocol. Samples (10 ml) were collected in acid citrate dextrose solution clinical vacutainers. All samples were stored at 4 1C until time of analysis and analyzed within 48 h of phlebotomy. Erythrocyte uptake of the potassium surrogate 86 Rubidium (Rb) was used to determine sodium/potassium ATPase ion transport activity. We utilized a modification of the method of Balzan et al. 9 Briefly, erythrocytes were washed three times in isotonic HEPES buffer solution with intervening ultracentrifugation at 2500 g at 4 1C for 20 min. The HEPES buffer solution contained calcium chloride, magnesium sulfate, sodium hydrogen phosphate, sodium chloride and glucose adjusted to a pH of 7.4 at 25 1C with sodium hydroxide. After washing, erythrocytes were suspended in HEPES buffer and adjusted to a final hematocrit of 50%. Equal aliquots were placed in three separate Eppendorf tubes. Comparable aliquots of the same pool of washed erythrocytes were prepared in similar manner and in triplicate with the presence of 0.1 mM ouabain. Comparison of these two sets of aliquots allowed for the determination of the ouabain-sensitive, erythrocyte Na/K ATPase ion transport. All aliquots underwent incubation with the isotope 86 Rb 5 mM per L (0.6 mCi per 150 ml). Incubations were terminated after 3 h with immersion of the tubes in ice-cold water. Radioactivity was assessed in a liquid scintillation counter. Uptake is expressed as Rb uptake per million cells per hour (nM/hr/10 6 cells). Statistical analysis included two sided, Student's t-test, reported as mean ± standard error. Statistical significance was considered at P<0.05.
Results
Twelve subjects were enrolled into each of the three groups. Demographical data are presented in Table 1 . There were no significant differences in terms of race, gestational age (for pregnant subjects), parity or tobacco use. The cesarean section rate was 83.3% in the severe preeclamptic group (10/12) . Subjects in the normotensive pregnant group were not in labor. There were no significant differences in electrolyte values for the two pregnant groups. Electrolyte analysis for the non-pregnant group was not specifically obtained.
Erythrocyte ouabain-sensitive Na/K ATPase ion transport activity is presented in Table 2 . The SP activity of normotensive pregnant women at delivery was significantly increased, by approximately 33%, compared with non-pregnant normotensive subjects (81.4 ± 2.4 vs 61.1 ± 2.1 nM/hr per 10 6 cells, P<0.05). Compared with normotensive pregnant subjects, SP activity from subjects with severe preeclampsia was significantly reduced, by approximately 43% (46.4±4.1 vs 81.4±2.4 nM/hr per 10 6 cells, P<0.05).
Discussion
The present study of erythrocyte, ouabain-sensitive Na/K ATPase (SP) activity as estimated by rubidium uptake shows a marked (43%) reduction in subjects with severe preeclampsia compared with women with gestational age-matched, uncomplicated pregnancies. SP activity in the latter group was increased compared with non-pregnant, normotensive women, in agreement with some, [10] [11] [12] [13] [14] but not all, [14] [15] [16] [17] previously published studies. Previous estimates of erythrocyte SP function in preeclampsia using direct measurements as opposed to indirect surrogates, such as transport rate constant, intracellular sodium concentration or number of ouabain-binding sites, have also been inconsistent, showing increased, [16] [17] [18] decreased 19, 20 or unchanged 12,15,21 -23 activity. This heterogeneity is unlikely to be entirely explained by differences in methods, as no correlation between results and technique is obvious. Erythrocyte sodium/potassium ATPase activity in preeclampsia CD Adair et al Rather, the inconsistent results suggest that erythrocyte SP function in pregnancy and preeclampsia may be affected by uncontrolled variables and small sample sizes. In comparing normal pregnancy to preeclampsia, one possible cause of heterogeneity might be variability in the population of patients selected in each study. Thus, most investigators have included both pregnancy-induced hypertension and mild and severe preeclampsia in their study population, and have obtained blood samples at various time points in the pregnancy. One strength of the present study is that we included only patients who met the criteria for severe preeclampsia, and obtained blood samples within 4 h prior to delivery. Another strength is that we used the most reliable assay for erythrocyte SP activity, avoiding harsh conditions that might remove substances bound to the membrane. Moreover, this method has been shown to detect erythrocyte SP inhibitory activity of EDLF extracted from cord blood of healthy newborns from normal pregnancies. 24 Magnesium was given to all patients as treatment for preeclampsia, but all SP activity measurements were performed in the same buffer with a constant magnesium concentration. Furthermore, increased magnesium concentrations are known to increase Na/K ATPase activity in various assays. 25 Other uncontrolled factors that may affect SP function include the lipid content of erythrocyte membranes, specifically the cholesterol phospholipid ratio (C/PL), and the presence of oxidative stress in preeclampsia. Erythrocyte SP activity is inversely related to membrane cholesterol content, 26, 27 and several studies have consistently shown increased erythrocyte membrane C/PL in normal pregnancy 28 and in pregnancy-induced hypertension. 29, 30 Although no studies of erythrocyte ion transport in pregnancy, including the present one, have controlled for this variable, an increased C/PL of platelet membranes from women with preeclampsia compared with normal pregnancy has been demonstrated. 31 Oxidative stress is generally recognized as a feature of preeclampsia that may cause some of the clinical manifestations. 32, 33 Oxidative damage to erythrocyte membranes could result in decreased SP activity as has been suggested in essential hypertension. 34 None of the previous studies or the present one have controlled for this possibility.
Although many studies show increased circulating levels of factors that cross-react with anti-digoxin or anti-ouabain antibodies in patients with normal pregnancies and with preeclampsia, 3 the question has been raised as to whether these immunoreactive factors have the biologic activity of digitalis glycosides. 35, 36 This question is important as biologically inactive cross-reacting substances are unlikely to have pathophysiologic significance in preeclampsia. The present results provide additional support for a circulating, biologically active SP inhibitor in patients with severe preeclampsia, presumably one or more of the EDLF demonstrated by immunoassays. 3 One proof of the concept that a circulating EDLF causes inhibition of erythrocyte SP activity would be to reverse the pump inhibition with an agent that binds and removes the EDLF from its receptor. One such agent is a commercially available anti-digoxin antibody (Digibind, Research Triangle Park, NC, USA; GlaxoSmithKline, Research Triangle Park, NC, USA) developed for the treatment of digoxin intoxication. Digibind has been used as an inhibitor of EDLF in a variety of experiments, including treatment of severe preeclampsia. 3 With respect to the present studies, it should be noted that Digibind has been shown to reverse the erythrocyte SP inhibition induced by an EDLF purified from neonatal (cord) blood 37 and the inhibition of erythrocyte SP activity caused by sera from patients with severe preeclampsia at delivery. 38 In addition, a recent double blind, placebo-controlled clinical trial (www.ClinicalTrials.gov no. NCT 00158743) showed that Digibind prevented the decline of glomerular filtration rate (GFR) that occurred just prior to delivery in patients with severe preeclampsia. 39 This effect could have been due to the reversal of an EDLF-induced renal vasoconstriction.
If a circulating EDLF causes SP inhibition in vascular smooth muscle as well as erythrocytes, 4 it could contribute to the generalized vasoconstriction observed in severe preeclampsia. 40 This effect could be synergistic with any vasoconstrictor factors induced by the disordered angiogenesis recently described in preeclampsia.
1,2 Additional studies will be needed to further characterize the pathophysiologic significance of pregnancyinduced changes in circulating EDLF and erythrocyte SP activity.
